Accelerating Hope for Children with Ultra-Rare Neurodegenerative Diseases
The Vanguard Clinical Rare Disease Foundation (VCRDF) is dedicated to advancing therapies for ultra-rare pediatric diseases, particularly neuronopathic lysosomal storage disorders such as Batten disease and mucopolysaccharidoses (MPS). In a field where traditional drug development models often fall short due to limited commercial incentives and fragmented infrastructure, VCRDF works to bring potentially life-changing treatments to children and families facing devastating diagnoses.
For these families, success is measured not only in survival, but in preserved cognition, mobility, communication, and valuable time together. Every month saved in development can have a profound impact on patient outcomes.
The Challenge
To support multiple emerging gene therapy programs, VCRDF required a manufacturing partner capable of delivering technical excellence while operating with the flexibility and urgency demanded by ultra-rare disease development. Traditional manufacturing models are often not designed to accommodate compressed timelines, evolving regulatory requirements, or the collaborative problem-solving needed to advance these highly specialized programs.
As a mission-driven nonprofit, VCRDF relies on external partners for GMP manufacturing expertise and scalable viral vector production. Previous industry experiences often reflected transactional relationships that lacked the responsiveness, adaptability, and shared commitment necessary to support rare disease innovation.
The Solution
Genezen distinguished itself as a true strategic partner, combining deep expertise in viral vector process development and GMP manufacturing with a highly collaborative approach. Rather than simply executing defined tasks, Genezen worked alongside VCRDF to address challenges proactively, providing scientific guidance, technical troubleshooting, risk mitigation support, and timeline optimization throughout the development process.
Recognizing the unique demands of ultra-rare disease programs, Genezen tailored its approach through transparent communication, engaged project oversight, and the flexibility to respond quickly to evolving program needs and regulatory considerations. This close partnership enabled accelerated development activities while maintaining rigorous quality and compliance standards.
Beyond technical execution, Genezen demonstrated a strong understanding of the human impact behind every program. By aligning around a shared mission to improve outcomes for children with progressive neurodegenerative diseases, Genezen helped foster a trusted, purpose-driven collaboration focused on delivering therapies to patients as quickly and responsibly as possible.
“For organizations like ours, this work is never just about manufacturing timelines, regulatory milestones, or technical execution. Behind every decision is a child whose disease is progressing in real time and a family desperately fighting for more time, more memories, and more hope. Genezen consistently demonstrated that level of commitment, compassion, and shared purpose throughout this collaboration.”
Tiffany Sepp,
CEO, Vanguard Clinical, Inc. and
Founder, Vanguard Clinical Rare Disease Foundation
